APA (7th ed.) Citation

CH, W., YC, O., HC, F., CC, T., YW, W., YY, C., . . . H, L. (2026). Evaluating homologous recombination status and the efficacy/safety of PARP inhibitors in advanced epithelial ovarianl cancer: A single-institute preliminary experience. Taiwanese journal of obstetrics & gynecology, 65(4), 737. https://doi.org/10.1016/j.tjog.2025.12.015

Chicago Style (17th ed.) Citation

CH, Wu, Ou YC, Fu HC, Tsai CC, Wang YW, Chen YY, Huang SW, and Lin H. "Evaluating Homologous Recombination Status and the Efficacy/safety of PARP Inhibitors in Advanced Epithelial Ovarianl Cancer: A Single-institute Preliminary Experience." Taiwanese Journal of Obstetrics & Gynecology 65, no. 4 (2026): 737. https://doi.org/10.1016/j.tjog.2025.12.015.

MLA (9th ed.) Citation

CH, Wu, et al. "Evaluating Homologous Recombination Status and the Efficacy/safety of PARP Inhibitors in Advanced Epithelial Ovarianl Cancer: A Single-institute Preliminary Experience." Taiwanese Journal of Obstetrics & Gynecology, vol. 65, no. 4, 2026, p. 737, https://doi.org/10.1016/j.tjog.2025.12.015.